Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A cfr-like gene cfr(C) conferring linezolid resistance is common in Clostridium difficile.

Candela T, Marvaud JC, Nguyen TK, Lambert T.

Int J Antimicrob Agents. 2017 Sep;50(3):496-500. doi: 10.1016/j.ijantimicag.2017.03.013. Epub 2017 Jun 27.

PMID:
28663118
2.

Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins.

Batah J, Kobeissy H, Bui Pham PT, Denève-Larrazet C, Kuehne S, Collignon A, Janoir-Jouveshomme C, Marvaud JC, Kansau I.

Sci Rep. 2017 Jun 12;7(1):3256. doi: 10.1038/s41598-017-03621-z.

3.

Arr-cb Is a Rifampin Resistance Determinant Found Active or Cryptic in Clostridium bolteae Strains.

Marvaud JC, Lambert T.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00301-17. doi: 10.1128/AAC.00301-17. Print 2017 Aug.

5.

Clostridium difficile flagella predominantly activate TLR5-linked NF-κB pathway in epithelial cells.

Batah J, Denève-Larrazet C, Jolivot PA, Kuehne S, Collignon A, Marvaud JC, Kansau I.

Anaerobe. 2016 Apr;38:116-124. doi: 10.1016/j.anaerobe.2016.01.002. Epub 2016 Jan 11.

PMID:
26790921
6.

Distribution of the vanG-like gene cluster in Clostridium difficile clinical isolates.

Ammam F, Marvaud JC, Lambert T.

Can J Microbiol. 2012 Apr;58(4):547-51. doi: 10.1139/w2012-002. Epub 2012 Mar 12.

PMID:
22409319
7.

Clostridium clostridioforme and Atopobium minutum clinical isolates with vanB-type resistance in France.

Marvaud JC, Mory F, Lambert T.

J Clin Microbiol. 2011 Sep;49(9):3436-8. doi: 10.1128/JCM.00308-11. Epub 2011 Jul 20.

8.

Analysis of the mobilization functions of the vancomycin resistance transposon Tn1549, a member of a new family of conjugative elements.

Tsvetkova K, Marvaud JC, Lambert T.

J Bacteriol. 2010 Feb;192(3):702-13. doi: 10.1128/JB.00680-09. Epub 2009 Dec 4.

9.

Differential requirement for the translocation of clostridial binary toxins: iota toxin requires a membrane potential gradient.

Gibert M, Marvaud JC, Pereira Y, Hale ML, Stiles BG, Boquet P, Lamaze C, Popoff MR.

FEBS Lett. 2007 Apr 3;581(7):1287-96. Epub 2007 Feb 28.

10.

Organization and regulation of the neurotoxin genes in Clostridium botulinum and Clostridium tetani.

Raffestin S, Marvaud JC, Cerrato R, Dupuy B, Popoff MR.

Anaerobe. 2004 Apr;10(2):93-100.

PMID:
16701505
12.

Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.

Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, Raffestin S, Popoff MR, Marvaud JC.

FEBS Lett. 2004 Aug 13;572(1-3):299-306.

13.
14.

[Botulism: the agent, mode of action of the botulinum neurotoxins, forms of acquisition, treatment and prevention].

Marvaud JC, Raffestin S, Popoff MR.

C R Biol. 2002 Aug;325(8):863-78; discussion 879-83. French.

PMID:
12391898
15.

Clostridium perfringens iota toxin. Mapping of the Ia domain involved in docking with Ib and cellular internalization.

Marvaud JC, Stiles BG, Chenal A, Gillet D, Gibert M, Smith LA, Popoff MR.

J Biol Chem. 2002 Nov 15;277(46):43659-66. Epub 2002 Sep 6.

16.

Clostridium perfringens iota toxin: characterization of the cell-associated iota b complex.

Stiles BG, Hale ML, Marvaud JC, Popoff MR.

Biochem J. 2002 Nov 1;367(Pt 3):801-8.

17.

Transcytosis of iota-toxin across polarized CaCo-2 cells.

Richard JF, Mainguy G, Gibert M, Marvaud JC, Stiles BG, Popoff MR.

Mol Microbiol. 2002 Feb;43(4):907-17.

19.

[Mechanism of action and therapeutic uses of botulinum and tetanus neurotoxins].

Popoff MR, Marvaud JC, Raffestin S.

Ann Pharm Fr. 2001 May;59(3):176-90. Review. French.

PMID:
11427819
20.

Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.

Marvaud JC, Smith T, Hale ML, Popoff MR, Smith LA, Stiles BG.

Infect Immun. 2001 Apr;69(4):2435-41.

21.

Regulation of the toxinogenesis in Clostridium botulinum and Clostridium tetani.

Marvaud JC, Raffestin S, Gibert M, Popoff MR.

Biol Cell. 2000 Sep;92(6):455-7. Review. No abstract available.

PMID:
11132708
22.

Bacterial toxins modifying the actin cytoskeleton.

Richard JF, Petit L, Gibert M, Marvaud JC, Bouchaud C, Popoff MR.

Int Microbiol. 1999 Sep;2(3):185-94. Review.

PMID:
10943412
23.
24.

Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes.

Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud JC, Popoff MR, Kozaki S, Oguma K.

FEBS Lett. 2000 Feb 11;467(2-3):179-83.

25.

Involvement of small GTPases in Mycoplasma fermentans membrane lipoproteins-mediated activation of macrophages.

Rawadi G, Zugaza JL, Lemercier B, Marvaud JC, Popoff M, Bertoglio J, Roman-Roman S.

J Biol Chem. 1999 Oct 22;274(43):30794-8.

26.

G-protein-stimulated phospholipase D activity is inhibited by lethal toxin from Clostridium sordellii in HL-60 cells.

El Hadj NB, Popoff MR, Marvaud JC, Payrastre B, Boquet P, Geny B.

J Biol Chem. 1999 May 14;274(20):14021-31.

27.

TetR is a positive regulator of the tetanus toxin gene in Clostridium tetani and is homologous to botR.

Marvaud JC, Eisel U, Binz T, Niemann H, Popoff MR.

Infect Immun. 1998 Dec;66(12):5698-702.

28.

botR/A is a positive regulator of botulinum neurotoxin and associated non-toxin protein genes in Clostridium botulinum A.

Marvaud JC, Gibert M, Inoue K, Fujinaga Y, Oguma K, Popoff MR.

Mol Microbiol. 1998 Aug;29(4):1009-18.

29.

Botulinal neurotoxin C1 complex genes, clostridial neurotoxin homology and genetic transfer in Clostridium botulinum.

Hauser D, Gibert M, Marvaud JC, Eklund MW, Popoff MR.

Toxicon. 1995 Apr;33(4):515-26.

PMID:
7570637
30.

[Stuttering: what does it tell us (body and speech)? What can be proposed (body and psyche)?].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1992;113(4):295-303. French.

PMID:
1344544
31.

[Speech therapy and psychosomatics: a double language].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1988;109(4):307-10. French. No abstract available.

PMID:
3238191
32.

[The voice and words].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1987;108(4):275-81. French. No abstract available.

PMID:
3432773
33.

[Relaxation in voice pathology].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1985;106(4):299-300. French. No abstract available.

PMID:
3832231
34.

[The specificity of speech therapy. Identity of the speech therapist].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1985;106(4):233-8. French. No abstract available.

PMID:
3832218
35.

[The symptom as evidence, lack of evidence, the evidence as symptom].

Marvaud J.

Rev Laryngol Otol Rhinol (Bord). 1983;104(4):307-12. French. No abstract available.

PMID:
6680438
36.

[The development of schizophrenia since the use of neuroleptics].

Bourgeois M, Marvaud J.

Ann Med Psychol (Paris). 1968 Jul;2(2):236-42. French. No abstract available.

PMID:
5684180

Supplemental Content

Loading ...
Support Center